A study to evaluate the effectiveness of Marma therapy and Nasya Therapy in the management of Migraine.

Comparative Clinico-Anatomical Study To Evaluate The Efficacy Of Marma Chikitsa And Shadbindu Taila Nasya In The Management Of Ardhavbhedaka - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105566

Enrollment

Registered

2026-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G430- Migraine without aura

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with Ardhavbhedaka (migraine) as per classical Ayurvedic texts and fulfilling the ICHD-3 criteria for migraine without aura. 2. Age between 14 and 60 years. 3. Both male and female patients. 4. Patients willing to give informed consent and adhere to the study protocol. 5. Patients with a history of migraine for at least 6 months. 6. Patients experiencing at least 2 migraine attacks per month.

Exclusion criteria

Exclusion criteria: 1. Patients with secondary headaches (e.g., due to brain tumor, sinusitis, glaucoma, etc.). 2. Patients with other severe systemic illnesses Like - uncontrolled hypertension, diabetes mellitus, renal failure, cardiac disorders. 3. Pregnant or lactating women. 4. Patients with psychiatric disorders. 5. Patients with a history of head injury or intracranial surgery. 6. Patients on prophylactic migraine medication for less than 3 months or unwilling to stop/adjust their current medication under medical supervision (if deemed necessary and safe). 7. Patients with known hypersensitivity to Shadbindu Taila ingredients. 8. Patients with nasal polyps, severe deviated nasal septum, or acute sinusitis.

Design outcomes

Primary

Measure	Time frame
Outcome Name: Change in Headache Intensity and Functional Disability. Method of Measurement: 1. Visual Analogue Scale (VAS): To assess the subjective intensity of pain on a scale of 0 to 10. 2. Migraine Disability Assessment (MIDAS) Score: To evaluate the impact of headache on the patients daily life and functional productivity.Timepoint: Baseline (Day 0), Mid-treatment (Day 15), Post-treatment (Day 30), and Follow-up (Day 45 & 60).	—

Measure

Time frame

Outcome Name: Change in Headache Intensity and Functional Disability. Method of Measurement: 1. Visual Analogue Scale (VAS): To assess the subjective intensity of pain on a scale of 0 to 10. 2. Migraine Disability Assessment (MIDAS) Score: To evaluate the impact of headache on the patients daily life and functional productivity.Timepoint: Baseline (Day 0), Mid-treatment (Day 15), Post-treatment (Day 30), and Follow-up (Day 45 & 60).

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactProf Jitendra Kumar Sharma

MADAN MOHAN MALVIYA GOVT AYURVED COLLEGE UDAIPUR RAJASTHAN

jk2011sharma@gmail.com9784988488

Outcome results